| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/01/2004 | US20040063938 Binding to aminobutyric acid |
| 04/01/2004 | US20040063913 Antibodies to human il-1beta |
| 04/01/2004 | US20040063794 Vehicle for topical delivery of anti-inflammatory compounds |
| 04/01/2004 | US20040063785 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use |
| 04/01/2004 | US20040063781 Compounds active at the glucocorticoid receptor II |
| 04/01/2004 | US20040063776 2-oxo-1-pyrrolidineacetamide derivatives are useful for treating cancer pain and other neuropathic pain |
| 04/01/2004 | US20040063760 Sodium channel modulatiors |
| 04/01/2004 | US20040063759 Administering to a mammal, for treatment or prevention of conditions that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, a piperidinone compound |
| 04/01/2004 | US20040063757 Urotensin-ll receptor antagonists |
| 04/01/2004 | US20040063755 Aromatic compounds containing hydroxyalkylaminoalkylphenylaminophenyl group; useful for treating pre-term labor, neurological disorders and cardiac disorders |
| 04/01/2004 | US20040063752 Monotherapy for the treatment of amyotrophic lateral sclerosis with cyclooxygenase-2 (COX-2) inhibitor(s) |
| 04/01/2004 | US20040063751 Such as N-(2-cyclohexyloxynitrophenyl)methane sulfonamide |
| 04/01/2004 | US20040063749 Excitatory amino acid receptor antagonists |
| 04/01/2004 | US20040063748 Such as 2-(4-amino-2,3,5-trimethylphenoxy)-N-methyl-N-(4-piperidinyl)acetamide which has neuroprotective effects by inducing calcium binding proteins |
| 04/01/2004 | US20040063742 Such as 5-(4-Chlorophenyl)-8-methyl-6,7,8,9-tetrahydro-1-H-pyrrolo(3.2-h)isoquinoline-2,3-dione-3-oxime-(phenyl))urea; kits; drug screening |
| 04/01/2004 | US20040063741 Dopamine receptor agonist for treatment of movement disorders/Parkinson's disease |
| 04/01/2004 | US20040063735 Calcitonin gene related peptide receptor antagonists |
| 04/01/2004 | US20040063731 Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists |
| 04/01/2004 | US20040063728 Such as (S)-8-(8-ethyoxy-2,3-dihydro-benzo(1,4)dioxin-2-ylmethyl)-3-naphthalen-2-yl -8-aza-bicyclo(3.2.1)octan-3-ol; for treatment of Alzheimer's disease |
| 04/01/2004 | US20040063727 Rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, cancer, restenosis; synthesis |
| 04/01/2004 | US20040063725 Binding neuropeptide Y receptors; hypertension, angina, atherosclerosis, depression, anxiety, inflammation, allergies |
| 04/01/2004 | US20040063724 Neurotransmitter 5-hydroxytryptamine-6 (5-HT6) antagonists |
| 04/01/2004 | US20040063723 One pot synthesis; formylation, oximination, cyanation, saponification and amidation of indole ester |
| 04/01/2004 | US20040063720 Tyrosine kinase inhibitors |
| 04/01/2004 | US20040063714 Triazolo-pyridazine derivatives as ligands for GABA receptors |
| 04/01/2004 | US20040063709 Acute and chronic inflammatory disorders; cancer |
| 04/01/2004 | US20040063707 Azaindole kinase inhibitors |
| 04/01/2004 | US20040063704 Central nervous system disorders including depression and/or anxiety; 5-HT1 type receptor and/or serotonin reuptake inhibition activity |
| 04/01/2004 | US20040063694 2-ethyl-10-(4-methyl-1-piperazinyl)-4H-thieno(2,3-b)(1,5) benzodiazepine; antipsychotic; does not elevate cholesterol levels |
| 04/01/2004 | US20040063693 5-HT2A receptor related disorders; such as 1-(2-(2-fluoro-4-nitrophenoxy)ethyl)-3-(1piperazinyl)-2(1H)-pyrazinone |
| 04/01/2004 | US20040063692 Bazedoxifene treatment regimens |
| 04/01/2004 | US20040063691 Preparation and use of imidazole derivatives for treatment of obesity |
| 04/01/2004 | US20040063690 Cardiovascular disorders; guanylate cyclase activation; diseases associated with disturbed cyclic guanosine monophosphate balance |
| 04/01/2004 | US20040063688 CCR1 receptor antagonists; such as 5-chloro-2-(2-(-3-(4-fluoro-phenoxy)-8-aza-bicyclo(3.2.1)oct-8-yl)-2-oxo -ethoxy)-benzamide |
| 04/01/2004 | US20040063687 Cardiac arrhythmias; potassium channel function inhibitors; such as 7-(3,4-Dichlorophenyl)-6-(5-fluoro-1-methyl-1H-benzimidazol-2-yl)-4,7 -dihydro-5-(methoxymethyl)pyrazolo-(1,5-a)pyrimidine |
| 04/01/2004 | US20040063679 Amidino and guanidino peptidyl compounds; autoimmune diseases |
| 04/01/2004 | US20040063670 Use of bisphosphonates for pain treatment |
| 04/01/2004 | US20040063661 Treatment of statin side effects |
| 04/01/2004 | US20040063647 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
| 04/01/2004 | US20040063644 Urea and urethane derivatives as integrin inhibitors |
| 04/01/2004 | US20040063643 Bombesin antagonists |
| 04/01/2004 | US20040063622 Methods and compositions for treating flaviviruses and pestiviruses |
| 04/01/2004 | US20040063621 Heterocarpine, a human ghrh-binding protein |
| 04/01/2004 | US20040063612 For therapy of neurodegenerative diseases |
| 04/01/2004 | US20040063610 For therapy of mammal having a transected peripheral nerve or injured spinal cord |
| 04/01/2004 | US20040063131 Comprises neuroendocrine-specific proteins-like polypeptides (NSPLP) for diagnosis, prevention and treatment of neurodegenerative and cell proliferative diseases |
| 04/01/2004 | US20040062812 Drug in mixture of matrix forming polymer and ion exchange resin |
| 04/01/2004 | US20040062800 Compressed matrix tablet; mixture of drug and swellable polymer; side effect reduction |
| 04/01/2004 | US20040062724 Thin, flexible, multilayer film; applying, adhesion to teeth; supplying active materials |
| 04/01/2004 | US20040061039 Furnace mount and method of installation |
| 04/01/2004 | DE10244397A1 Cholinascorbat-Formulierungen Choline formulations |
| 04/01/2004 | CA2499326A1 Heterocyclic substituted piperazines for the treatment of schizophrenia |
| 04/01/2004 | CA2499200A1 Use of compounds in the treatment of dyskinesia |
| 04/01/2004 | CA2498890A1 Modified release formulations of oxcarbazepine and derivatives thereof |
| 04/01/2004 | CA2498662A1 Phenol derivatives and their use as rotamase inhibitors |
| 04/01/2004 | CA2498335A1 4-pyrrolidino-phenyl-benzyl ether derivatives |
| 04/01/2004 | CA2498046A1 Opiate analogs selective for the delta-opioid receptor |
| 04/01/2004 | CA2497903A1 Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient |
| 04/01/2004 | CA2496765A1 2,7-substituted indoles and their use as 5-ht6 modulators |
| 04/01/2004 | CA2496727A1 Process for producing paroxetine hydrochloride hydrate |
| 04/01/2004 | CA2496292A1 Selective phosphodiesterase 9a inhibitors as medicaments for improving cognitive processes |
| 03/31/2004 | EP1403371A1 Novel polypeptide and use thereof |
| 03/31/2004 | EP1403279A1 Protein polymer having unfold activity on higher-order structure of protein |
| 03/31/2004 | EP1403270A1 Pde iv inhibitors |
| 03/31/2004 | EP1403256A1 Fused imidazole derivative |
| 03/31/2004 | EP1403255A1 Rho KINASE INHIBITORS |
| 03/31/2004 | EP1403243A1 Compounds used to treat alcoholism |
| 03/31/2004 | EP1402888A1 The use of substituted carbocyclic compounds as rotamases inhibitors |
| 03/31/2004 | EP1402786A1 Ximenynic acid |
| 03/31/2004 | EP1402270A1 Identification of modulators of neurotransmitter activity of xanthurenic acid |
| 03/31/2004 | EP1402266A2 Determination of risk and treatment of complications of prematurity |
| 03/31/2004 | EP1402066A2 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 03/31/2004 | EP1402054A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 03/31/2004 | EP1402034A2 Identification of ses-1 and the uses of the same |
| 03/31/2004 | EP1402009A1 Novel mixed lineage kinase (7) (mlk7) polypeptide, polynucleotides encoding the same, and methods of use thereof |
| 03/31/2004 | EP1402005A1 A method of purification of cells |
| 03/31/2004 | EP1402000A2 Structural and cytoskeleton-associated proteins |
| 03/31/2004 | EP1401999A2 B7 related protein-2 molecules and uses thereof |
| 03/31/2004 | EP1401870A2 Antibodies against tumor necrosis factor delta (april) |
| 03/31/2004 | EP1401863A1 Somatostatin-dopamine chimeric analogs |
| 03/31/2004 | EP1401862A2 Peptide compounds for counteracting reactive oxygen species and free radicals |
| 03/31/2004 | EP1401853A1 Modulators of pharmacological agents |
| 03/31/2004 | EP1401841A1 Substituted 1-oxa-2,8-diaza-spiro 4,5]dec-2-ene derivatives as medicaments for the treatment of pain |
| 03/31/2004 | EP1401840A1 Novel 4-amino-5,6-substituted thiopheno 2,3-d]pyrimidines |
| 03/31/2004 | EP1401839A1 Antidepressant (sssri) azaheterocyclymethyl derivatives of 7,8-dihydro-3h-t,9-dioxa-1,3-diazacyclopenta a]naphthalene |
| 03/31/2004 | EP1401838A2 Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine |
| 03/31/2004 | EP1401837A1 Purine derivatives as a2b adenosine receptor antagonists |
| 03/31/2004 | EP1401831A1 Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
| 03/31/2004 | EP1401822A1 Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 03/31/2004 | EP1401821A1 Novel phenylalkyl diamine and amide analogs |
| 03/31/2004 | EP1401820A1 5-ht receptor ligands and uses thereof |
| 03/31/2004 | EP1401819A1 5-ht receptor ligands and uses thereof |
| 03/31/2004 | EP1401813A1 New indole derivatives with 5-ht6 receptor affinity |
| 03/31/2004 | EP1401812A1 4-piperazinylindole derivatives with 5-ht6 receptor affinity |
| 03/31/2004 | EP1401810A1 Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use |
| 03/31/2004 | EP1401809A1 Tryptase inhibitors |
| 03/31/2004 | EP1401808A2 Gpe analogs and peptidomimetics |
| 03/31/2004 | EP1401805A1 Valproyltaurinamide derivatives as anticonvulsant and cns active agents |
| 03/31/2004 | EP1401498A1 Anti-ngf antibodies for the treatment of various disorders |
| 03/31/2004 | EP1401485A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 4-(2- 4-methane sulfonyl oxyphenyl ethoxy)phenyl] propanoic acid or 3- 4- 2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl -(s)-2-ethoxy propanoic acid and insulin |